12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erbitux cetuximab: Phase III data

Merck's Merck Serono S.A. division said that a pre-specified interim analysis of the open-label, European Phase III PETACC-8 trial in 2,559 patients does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. Specifically,...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >